Novel Small Molecule Inhibitor of Tyk2: Lucrative Therapeutic Target in Lupus
Abstract
This research project is directed at exploring the use of small molecule inhibitors of Tyk2 and Jak1 aimed at ameliorating the chronic inflammatory milieu and high titers of auto-antibodies in lupus, decrease disease symptoms and prolong survival in the (NZBxNZW)F1 mouse model of lupus. In our initial findings we report that treatment of lupus-prone (NZBxNZW)F1 mice with small molecule inhibitor of Tyk2/Jak1 significantly lowers the pathological auto-antibody production. The treatment also lead to a drop in the number of germinal centers in the spleen (NZBxNZW)F1 mice as well as a decrease in spleen weights. Over all, the treatment has shown potential for significantly improving the disease pathology in (NZBxNZW)F1 mouse model of lupus. We are in the process of performing experiments for the next phase of the proposal.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2017
- Accession Number
- AD1048482
Entities
People
- Abhishek Trigunaite
Organizations
- SRI International